BioRestorative Therapies (BRTX) director Katharyn Field files initial Form 3

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. director Katharyn Field has filed an initial statement of beneficial ownership on Form 3. The filing identifies her as a director, not an officer and not a ten percent owner, and does not report any specific transactions or holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/17/2026 - 05:02 PM Accepted by SEC EDGAR 06/17/2026 - 05:01 PM Learn about SEC filing dates

FAQ

What does the BioRestorative Therapies (BRTX) Form 3 filing report?

The Form 3 reports that Katharyn Field is a director of BioRestorative Therapies. It serves as her initial statement of beneficial ownership, with no specific share amounts or transactions disclosed in the available data.

Is Katharyn Field a ten percent owner of BioRestorative Therapies (BRTX)?

No, the Form 3 indicates Katharyn Field is not a ten percent owner of BioRestorative Therapies. She is identified only as a director, and no large ownership position is shown in the summary data provided.

Does the BRTX Form 3 for Katharyn Field show any stock transactions?

No, the Form 3 data for Katharyn Field shows no reported stock transactions. Transaction counts for buys, sells, exercises, gifts, and tax withholdings are all zero, indicating this filing is purely an initial ownership statement.

Does the BioRestorative Therapies (BRTX) Form 3 disclose option or derivative holdings?

No, the derivative summary in the Form 3 is empty, indicating no listed options or other derivative securities. The filing does not show remaining derivative positions for Katharyn Field in the available structured data.

What is the role of Katharyn Field at BioRestorative Therapies (BRTX) per the Form 3?

The Form 3 identifies Katharyn Field as a director of BioRestorative Therapies. She is not listed as an officer and holds no officer title in the filing’s structured data, clarifying her governance role at the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Field Katharyn

(Last) (First) (Middle)

40 MARCUS DRIVE

C/O BIORESTORATIVE THERAPIES, INC.

(Street)

MELVILLE NEW YORK 11747

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/10/2026

3. Issuer Name and Ticker or Trading Symbol
BioRestorative Therapies, Inc. [ BRTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Katharyn Field	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)